A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria

American Journal of Cardiology

Volumn 88, Issue 11, 2001, Pages 1287-1290

  Kini, Annapoorna S ^a   Reich, David ^a   Mitre, Cristina A ^a   Sharma, Samin K ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ACUTE HEART INFARCTION; ANGIOGRAPHY; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; Q WAVE; REVASCULARIZATION; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0035581265     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)02089-6     Document Type: Article

References (17)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
3. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
4. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
6. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
7. Randomized placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: CAPTURE study
8. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
9. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized placebo-controlled trial
10. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course
11. Minimal myocardial damage during coronary intervention is associated with impaired outcome
12. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after placement of coronary artery stents in acute myocardial infarction
13. Cardioprotective effect of prior β-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: Benefit is extended to improvement in intermediate-term survival
14. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: Implications for patient selection
15. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
16. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicenter randomized trial
17. Comparison of two platelet glycoprotein IIb/IIIa inhibitors tirofiban and abciximab for the prevention of ischemic events with percutaneous coronary revascularization